These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

921 related articles for article (PubMed ID: 31025557)

  • 21. Increased prevalence and risk of non-alcoholic fatty liver disease in overweight and obese patients with Type 2 diabetes in South China.
    Yi M; Chen RP; Yang R; Chen H
    Diabet Med; 2017 Apr; 34(4):505-513. PubMed ID: 27334577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-alcoholic fatty liver disease and its associations among adolescents in an urban, Sri Lankan community.
    Rajindrajith S; Pathmeswaran A; Jayasinghe C; Kottahachchi D; Kasturiratne A; de Silva ST; Niriella MA; Dassanayake AS; de Silva AP; de Silva HJ
    BMC Gastroenterol; 2017 Nov; 17(1):135. PubMed ID: 29187144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD).
    Johnston MP; Patel J; Byrne CD
    Curr Pharm Des; 2020; 26(10):1079-1092. PubMed ID: 32003662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive Value of Adiposity Level, Metabolic Syndrome, and Insulin Resistance for the Risk of Nonalcoholic Fatty Liver Disease Diagnosis in Obese Children.
    Prokopowicz Z; Malecka-Tendera E; Matusik P
    Can J Gastroenterol Hepatol; 2018; 2018():9465784. PubMed ID: 29854716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-alcoholic fatty liver disease in pediatric type 2 diabetes: Metabolic and histologic characteristics in 38 subjects.
    Newfield RS; Graves CL; Newbury RO; Schwimmer JB; Proudfoot JA; Say DS; Feldstein AE
    Pediatr Diabetes; 2019 Feb; 20(1):41-47. PubMed ID: 30467936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones.
    García-Monzón C; Vargas-Castrillón J; Porrero JL; Alonso MT; Bonachía O; Castillo MJ; Marcos A; Quirós E; Ramos B; Sánchez-Cabezudo C; Villar S; Sáez A; Rodríguez de Cía J; del Pozo E; Vega-Piris L; Soto-Fernández S; Lo Iacono O; Miquilena-Colina ME
    Liver Int; 2015 Aug; 35(8):1983-91. PubMed ID: 25708133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of biopsy-proven non-alcoholic fatty liver disease in severely obese subjects without metabolic syndrome.
    Qureshi K; Abrams GA
    Clin Obes; 2016 Apr; 6(2):117-23. PubMed ID: 26856683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic syndrome and biochemical changes among non-alcoholic fatty liver disease patients attending a tertiary care hospital of Nepal.
    Pardhe BD; Shakya S; Bhetwal A; Mathias J; Khanal PR; Pandit R; Shakya J; Joshi HO; Marahatta SB
    BMC Gastroenterol; 2018 Jul; 18(1):109. PubMed ID: 29980170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cholesterol efflux capacity is impaired in subjects with an elevated Fatty Liver Index, a proxy of non-alcoholic fatty liver disease.
    van den Berg EH; Gruppen EG; Ebtehaj S; Bakker SJL; Tietge UJF; Dullaart RPF
    Atherosclerosis; 2018 Oct; 277():21-27. PubMed ID: 30170220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and its association with cardiovascular disease.
    Vanjiappan S; Hamide A; Ananthakrishnan R; Periyasamy SG; Mehalingam V
    Diabetes Metab Syndr; 2018 Jul; 12(4):479-482. PubMed ID: 29402657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.
    Vernon G; Baranova A; Younossi ZM
    Aliment Pharmacol Ther; 2011 Aug; 34(3):274-85. PubMed ID: 21623852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects.
    Kim SS; Cho HJ; Kim HJ; Kang DR; Berry JR; Kim JH; Yang MJ; Lim SG; Kim S; Cheong JY; Cho SW
    Dig Liver Dis; 2018 Apr; 50(4):370-377. PubMed ID: 29398414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of non alcoholic fatty liver and Non alcoholic Steatohepatitis in Peshawar Cantonment, Khyber Pakhtunkhwa, Pakistan.
    Shah AS; Khan S; Rahim H; Chishti KA; Khan AG
    Pak J Pharm Sci; 2018 Jan; 31(1):193-198. PubMed ID: 29348103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonalcoholic fatty liver disease - A multisystem disease?
    Mikolasevic I; Milic S; Turk Wensveen T; Grgic I; Jakopcic I; Stimac D; Wensveen F; Orlic L
    World J Gastroenterol; 2016 Nov; 22(43):9488-9505. PubMed ID: 27920470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.
    Hydes TJ; Summers N; Brown E; Alam U; Thomaides-Brears H; Wilding JPH; Cuthbertson DJ
    Diabet Med; 2020 Nov; 37(11):1793-1806. PubMed ID: 32619031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?
    Firneisz G
    World J Gastroenterol; 2014 Jul; 20(27):9072-89. PubMed ID: 25083080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.